# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Needham analyst Mike Matson reiterates AtriCure (NASDAQ:ATRC) with a Buy and maintains $40 price target.
Canaccord Genuity analyst William Plovanic maintains AtriCure (NASDAQ:ATRC) with a Buy and lowers the price target from $57 ...
JP Morgan analyst Robbie Marcus maintains AtriCure (NASDAQ:ATRC) with a Overweight and lowers the price target from $42 to $34.
Needham analyst Mike Matson maintains AtriCure (NASDAQ:ATRC) with a Buy and lowers the price target from $46 to $40.
AtriCure (NASDAQ:ATRC) reported quarterly losses of $(0.25) per share which missed the analyst consensus estimate of $(0.23) by...